J. Safra Sarasin Holding AG Acquires Shares of 36,951 Pfizer Inc. $PFE

Key Points

• J. Safra Sarasin Holding AG opened a new position in Pfizer by acquiring 36,951 shares in Q4, valued at about $920,000.
• Pfizer beat Q4 estimates with $0.66 EPS (vs. $0.57 expected) and $17.56B in revenue (down 1.2% YoY); shares were up ~1.7% and the Street's consensus target is about $28.19 with an average "Hold" rating.
• Near-term catalysts include a Belgian court ordering Poland and Romania to accept €1.9B of Pfizer COVID vaccines, while negatives include paused U.S. recruitment for an updated COVID vaccine trial and reports of a South San Francisco research site closure.

J. Safra Sarasin Holding AG acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 36,951 shares of the biopharmaceutical company's stock, valued at approximately $920,000.

Other large investors also recently made changes to their positions in the company. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 645 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the 2nd quarter valued at about $30,000. True Wealth Design LLC increased its position in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the second quarter worth about $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.7%

Shares of NYSE:PFE opened at $28.56 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.64. The company has a 50 day moving average of $26.99 and a 200-day moving average of $25.77. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market cap of $162.41 billion, a price-to-earnings ratio of 21.00 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the business posted $0.63 earnings per share. Pfizer's revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to accept €1.9B (~$2.2B) of Pfizer COVID-19 vaccines, effectively locking in substantial near-term revenue and reducing delivery/collection uncertainty. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Analyst/market write-ups highlight PFE’s recent outperformance and upward technical momentum (trading above its 50- and 200-day SMAs, and positive earnings beats), which supports demand for the stock. Why Pfizer (PFE) Outpaced the Stock Market Today
• Positive Sentiment: Fresh real‑world data from a Swedish study on Ibrance (palbociclib) offers an incremental clinical signal for Pfizer’s oncology franchise, supporting pipeline upside expectations. Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors
• Neutral Sentiment: Pfizer finalized reshaping of ViiV Healthcare ownership (GSK/Shionogi deal) as it exits the joint HIV venture — a strategic reallocation that may free capital but reduces direct exposure to that HIV business. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Background and business-model pieces continue to circulate (how Pfizer makes money, sector commentary), useful for context but not immediate catalysts. How Pfizer Makes Money
• Negative Sentiment: Pfizer and BioNTech paused U.S. recruitment for a large updated COVID vaccine trial (adults 50–64) due to low enrollment — a setback for collecting pivotal U.S. data and could delay future vaccine updates or label expansion. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Critical pieces argue Pfizer’s large dividend may mask underlying growth challenges, keeping longer-term valuation concerns on investors’ radar. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site may signal internal cost-cutting or pipeline reprioritization; this can be seen as short-term disruption to R&D capacity. Pfizer is said to close South San Francisco research site

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Guggenheim upped their price objective on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. BMO Capital Markets reiterated an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Finally, UBS Group initiated coverage on Pfizer in a research note on Tuesday, January 6th. They issued a "neutral" rating and a $25.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $28.19.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.